Aileron Therapeutics Inc
General ticker "ALRN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $49.3M
Aileron Therapeutics Inc does not follow the US Stock Market performance with the rate: -22.9%.
Estimated limits based on current volatility of 7.0%: low 1.72$, high 1.98$
Factors to consider:
- Earnings for 18 months up through Q2 (+1 year) are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [1.51$, 4.35$]
- 2023-12-31 to 2024-12-30 estimated range: [1.18$, 3.27$]
Financial Metrics affecting the ALRN estimates:
- Negative: Non-GAAP EPS, $ of -6.02 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -67.95 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -21.66 <= 3.85
Short-term ALRN quotes
Long-term ALRN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $26.61MM | $27.65MM | $16.28MM |
| Operating Income | $-26.61MM | $-27.65MM | $-16.28MM |
| Non-Operating Income | $0.44MM | $0.32MM | $0.54MM |
| R&D Expense | $17.01MM | $17.97MM | $3.99MM |
| Income(Loss) | $-26.16MM | $-27.33MM | $-15.73MM |
| Profit(Loss) | $-26.16MM | $-27.33MM | $-15.73MM |
| Stockholders Equity | $43.90MM | $18.62MM | $6.89MM |
| Assets | $48.48MM | $22.01MM | $106.01MM |
| Operating Cash Flow | $-23.75MM | $-24.86MM | $-19.81MM |
| Capital expenditure | $0.16MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-35.92MM | $26.46MM | $16.20MM |
| Financing Cash Flow | $55.66MM | $0.00MM | $15.79MM |
| Earnings Per Share* | $-5.80 | $-5.95 | $-3.42 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.